clinical trial · NCT06814938
A Study of a Novel Precision Medicine Approach For Obesity
ObesitySemaglutidePlacebo
brief summary
This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
started
Feb 21, 2025
primary completion
Dec 1, 2027
completion
Nov 1, 2028
last updated
Jul 16, 2026
detailed description
The purpose of this study is to test the effectiveness of semaglutide 2.4 mg SQ weekly in patients with obesity with a positive MyPhenome test for abnormal postprandial satiety compared to patients with obesity with a negative MyPhenome test for abnormal postprandial satiety.
official title
A Novel Precision Medicine Approach For Obesity: A Randomized, Multi-Center Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol